Omeros (OMER) PT Raised to $4.00
Omeros (NASDAQ:OMER) had its price objective lifted by Bank of America from $2.44 to $4.00 in a report issued on Wednesday morning, The Fly reports.
A number of other brokerages have also recently commented on OMER. Zacks Investment Research upgraded Omeros from a sell rating to a hold rating in a research report on Wednesday, November 15th. Wedbush reiterated an outperform rating and set a $47.00 target price on shares of Omeros in a research report on Tuesday, November 28th. Maxim Group reiterated a buy rating and set a $24.00 target price on shares of Omeros in a research report on Monday, November 6th. HC Wainwright set a $30.00 target price on Omeros and gave the stock a buy rating in a research report on Tuesday, January 23rd. Finally, ValuEngine upgraded Omeros from a sell rating to a hold rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $30.38.
Shares of Omeros (NASDAQ OMER) opened at $11.25 on Wednesday. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74. The company has a market capitalization of $558.18, a PE ratio of -9.02 and a beta of 3.30. Omeros has a 1 year low of $10.52 and a 1 year high of $27.09.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.